icon-folder.gif   Conference Reports for NATAP  
 
  Paris Special EASL Meeting
Pais, France
September 23-24, 2016
Back grey_arrow_rt.gif
 
 
 
Ribavirin Management in HCV Genotype 4 Patients Receiving Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in the Phase 3 AGATE-I Study
 
 
  Reported by Jules Levin
EASL/AASLD - New Perspectives in Hepatitis C Virus Infection-The Roadmap for Cure, 23-24 September 2016, Paris, France
 
Christophe Hezode1, Tarek Hassanein2, Yves Horsmans3, Hermann Laferl4, Jose Luis Calleja5, Antonio Olveira6, Christophe Moreno7, George Papatheodoridis8, Magdy Elkhashab9, Marisol Martinez10, Yao Yu10, Rebecca Redman10, Roula Qaqish10, Niloufar Mobashery10, Tarik Asselah11 1H˘pital Henri Mondor, AP-HP, Universite Paris-Est, Inserm, Creteil, France; 2Southern California GI and Liver Centers and Southern California Research Center, Coronado, California, United States; 3Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium; 4Kaiser Franz Josef Hospital, 4th Medical Department with Infectious Diseases and Tropical Medicine, Vienna, Austria; 5Liver Unit. Hospital Universitario Puerta de Hierro, Universidad Autonoma de Madrid, CIBERehd, Madrid, Spain; 6Liver Unit. Hospital Universitario, La Paz, CIBERehd, Madrid, Spain; 7CUB H˘pital Erasme, Universite Libre de Bruxelles, Brussels, Belgium; 8Academic Department of Gastroenterology, Medical School of Nati onal and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece; 9Toronto Liver Centre, Toronto, Ontario, Canada; 10AbbVie Inc., North Chicago, Illinois, United States; 11Centre de Recherche sur l'Infl ammati on (CRI), Inserm UMR, Universite Paris Diderot, Service d'Hepatologie, AP-HP H˘pital Beaujon, Clichy, France

IAC1

IAC2

IAC3

IAC4

IAC5

IAC6

IAC7